MaaT Pharma Share Price
Stocks
MAAT
FR0012634822
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Euronext Paris
12:42:07 06/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.084 EUR | +8.40% |
|
+6.29% | -77.51% |
| 07:27am | Primary endpoint met in a validated phase 2a trial for MaaT Pharma |  |
| 10-20 | MaaT Pharma Gets Positive Feedback from US FDA to Develop MaaT034 Microbiome Therapy for Solid Tumors | MT |
| Market Cap | 18.84M 21.15M 17.24M 15.7M 29.59M 2B 30.39M 207M 82.8M 1.06B 79.37M 77.67M 3.34B | P/E 2026 * |
-0.47x | P/E 2027 * | -1.03x |
|---|---|---|---|---|---|
| Enterprise Value | 35.24M 39.55M 32.23M 29.35M 55.33M 3.74B 56.82M 387M 155M 1.98B 148M 145M 6.25B | EV / Sales 2026 * |
4.66x | EV / Sales 2027 * | 1.66x |
| Free-Float |
36.81% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| MAAT | Real-time | |
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| 4RD | Delayed | |
|
Börse Stuttgart
| 4RD | Delayed | |
|
Boerse Muenchen
| 4RD | Real-time | |
|
CBOE
| Real-time |
| 1 day | +8.20% | ||
| 1 week | +6.29% | ||
| Current month | +6.29% | ||
| 1 month | +9.29% | ||
| 3 months | -61.77% | ||
| 6 months | -82.83% | ||
| Current year | -77.51% |
| 1 week | 1 |  | 1.27 |
| 1 month | 0.9 | | 1.3 |
| Current year | 0.9 | | 8.62 |
| 1 year | 0.9 | | 8.62 |
| 3 years | 0.9 | | 9.96 |
| 5 years | 0.9 | | 14.4 |
| 10 years | 0.9 | | 14.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
CEO | Chief Executive Officer | - | 31/12/2013 |
Eric Soyer
DFI | Director of Finance/CFO | 59 | 31/10/2024 |
| Chief Tech/Sci/R&D Officer | - | 28/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
BRD | Director/Board Member | - | 31/12/2013 |
| Director/Board Member | 57 | 31/12/2013 | |
| Chairman | - | 31/05/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/05/26 | Buy | Founder | 2,000 | 0.0106% | ||
| 29/01/26 | Seventure Partners SA
| Sell | Company | 25,423 | 0.1356% | |
| 28/01/26 | Seventure Partners SA
| Sell | Company | 57,964 | 0.3091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.40% | +6.29% | -71.75% | -86.47% | 21.15M | |
| +3.80% | +8.10% | +63.78% | +77.70% | 69.4B | |
| -2.13% | -1.16% | +8.19% | +72.76% | 57.24B | |
| -2.31% | +1.65% | +23.18% | +97.59% | 57.62B | |
| +0.41% | -3.70% | +26.06% | +34.32% | 43.65B | |
| +2.51% | +4.22% | +20.49% | +110.71% | 44.03B | |
| -11.04% | -6.63% | +199.38% | +701.67% | 38.08B | |
| +7.50% | +13.58% | +29.07% | +64.46% | 36.31B | |
| -3.58% | -10.81% | +86.83% | +74.28% | 32.61B | |
| -2.18% | +7.06% | +36.06% | -4.95% | 25.47B | |
| Average | +0.23% | +1.86% | +42.13% | +114.21% | 40.44B | |
| Weighted average by Cap. | -0.32% | +3.12% | +51.10% | +130.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.56M 8.48M 6.91M 6.3M 11.87M 802M 12.19M 83.05M 33.21M 424M 31.84M 31.15M 1.34B | 32.35M 36.3M 29.59M 26.95M 50.79M 3.43B 52.16M 355M 142M 1.82B 136M 133M 5.73B |
| Net income | -33.37M -37.45M -30.52M -27.8M -52.4M -3.54B -53.81M -367M -147M -1.87B -141M -138M -5.91B | -10.99M -12.33M -10.05M -9.15M -17.25M -1.17B -17.72M -121M -48.28M -617M -46.28M -45.29M -1.95B |
| Net Debt | 16.4M 18.4M 15M 13.66M 25.74M 1.74B 26.44M 180M 72.04M 921M 69.06M 67.58M 2.91B | 34.82M 39.08M 31.85M 29.01M 54.67M 3.69B 56.15M 383M 153M 1.96B 147M 144M 6.17B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | €1.084 | +8.40% | 272,917 |
| 05/11/26 | €1.000 | -1.57% | 42,804 |
| 04/11/26 | €1.016 | 0.00% | 24,874 |
| 03/11/26 | €1.016 | -1.36% | 31,931 |
| 02/11/26 | €1.030 | +1.18% | 24,531 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- MAAT Stock
Select your edition
All financial news and data tailored to specific country editions
